Histological confirmation of breast cancer registration and self-reporting in England and Wales: A cohort study within the UK Collaborative Trial of Ovarian Cancer Screening

E. O. Fourkala, A. Gentry-Maharaj, M. Burnell, A. Ryan, R. Manchanda, A. Dawnay, I. Jacobs, M. Widschwendter, U. Menon

    Research output: Contribution to journalArticlepeer-review

    Abstract

    Background: In research studies, accurate information of cancer diagnosis is crucial. In women with breast cancer (BC), we compare cancer registration (CR) in England/Wales and self-reporting with independent confirmation. Methods: In the UK Collaborative Trial of Ovarian Cancer Screening, notification of BC diagnosed between randomisation and 31 December 2009 was obtained through (1) CR (17 October 2011) and (2) self-reporting using postal-questionnaire. Breast cancer was confirmed using a detailed questionnaire (BC questionnaire BCQ) completed by the treating clinician (gold standard). Apparent sensitivity and positive-predictive value of CR/self-reporting vs BCQ were calculated. Results: Of 1065 women with possible BC notification, diagnosis was confirmed in 932 (87.5%). A total of 3.1% (28 out of 918) of BC CR and 12.4% (128 out of 1032) of women with self-reported BC only had in-situ carcinoma on BCQ. Another 4.6% (43 out of 932) of BCQ-confirmed cancer did not have a BC registration, and 3.6% (34 out of 932) did not self-report BC. Apparent sensitivity of CR and self-reporting vs BCQ were 95.4 and 96.4%, respectively. Positive-predictive value of self-reporting (87.1%) was significantly lower than that of CR (96.8%). Women aged
    Original languageEnglish
    Pages (from-to)1910-1916
    Number of pages6
    JournalBritish Journal of Cancer
    Volume106
    Issue number12
    DOIs
    Publication statusPublished - 5 Jun 2012

    Keywords

    • breast cancer
    • cancer registry
    • self-reporting
    • UKCTOCS

    Fingerprint

    Dive into the research topics of 'Histological confirmation of breast cancer registration and self-reporting in England and Wales: A cohort study within the UK Collaborative Trial of Ovarian Cancer Screening'. Together they form a unique fingerprint.

    Cite this